pharma · Alzheimer's Disease · Type 2 Diabetes Mellitus · VTVT
vTv Therapeutics
vTv Therapeutics patent portfolio — 50 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 3980 Premier Dr, Suite 110, High Point, North Carolina 27265, US
- Employees
- 55
- Programs
- 14
- Drugs
- 2
- Patents
- 50
vTv Therapeutics patents
50 pharmaceutical patents indexed for vTv Therapeutics. 0 expire within 24 months.
vTv Therapeutics has 50 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12391658
Sulfoxide and sulfone glucokinase activators and methods of use thereof
granted -
US 12091407
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 11974989
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
granted -
US 11970457
Metabolites of [3-(4-(2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl)-phenoxy)-propyl]-diethyl-amine
granted -
US 11883383
Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
granted -
US 11833136
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
granted -
US 11649230
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 11524942
Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 yl}-phenoxy)-propyl]-diethyl-amine
granted -
US 11420942
Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
granted -
US 11420929
Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
granted -
US 11130753
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 11096946
Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
granted -
US 10980861
Glucokinase activator compositions for the treatment of diabetes
granted -
US 10952993
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
granted -
US 10947180
Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
granted -
US 10898475
Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
granted -
US 10889580
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 10588943
Glucokinase activator compositions for the treatment of diabetes
granted -
US 10568888
Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
granted -
US 10570126
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 10471066
Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
granted -
US 10463652
Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
granted -
US 10456406
Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
granted -
US 10391097
Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
granted -
US 10364233
Piperidine derivative and methods of use thereof
granted -
US 10363241
Substituted imidazole derivatives and methods of use thereof
granted -
US 10363244
Compositions comprising metformin and a glucokinase activator
granted -
US 10287284
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 10172840
Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof
granted -
US 10085990
Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
granted -
US 10064846
Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
granted -
US 10030011
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 10004782
Glucokinase activator compositions for the treatment of diabetes
granted -
US 9968613
Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
granted -
US 9855274
Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
granted -
US 9855251
Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
granted -
US 9833457
Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
granted -
US 9717710
Treatment of mild and moderate Alzheimer's disease
granted -
US 9707239
Compounds that modulate oxidative stress
granted -
US 9687489
Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
granted -
US 9663481
Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists
granted -
US 9598375
Substituted imidazole derivatives and methods of use thereof
granted -
US 9487493
Use of a PPAR-delta agonist for treating muscle atrophy
granted -
US 9447468
Compounds that modulate oxidative stress
granted -
US 9393245
Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
granted -
US 9359313
Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
granted -
US 9198901
Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof
granted -
US 9175003
Substituted azoanthracene derivatives and intermediates for preparation thereof
granted
Frequently asked questions
How many patents does vTv Therapeutics have?
50 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do vTv Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.